539 related articles for article (PubMed ID: 9046384)
1. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
Whitfield RM; Bechtel LM; Starich GH
Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
[TBL] [Abstract][Full Text] [Related]
2. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
[TBL] [Abstract][Full Text] [Related]
3. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
4. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
[TBL] [Abstract][Full Text] [Related]
5. AZT delta study: major European/Australian study finds combinations better than AZT alone.
King E
AIDS Treat News; 1995 Oct; (no 232):3-4. PubMed ID: 11362876
[TBL] [Abstract][Full Text] [Related]
6. Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study Group.
Moyle GJ; Walker M; Harris R; Kellagher A; Warburg M
Antivir Ther; 1996 Aug; 1(3):180-8. PubMed ID: 11322252
[TBL] [Abstract][Full Text] [Related]
7. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
Kelleher T; Cross A; Dunkle L
Clin Ther; 1999 Jul; 21(7):1182-92. PubMed ID: 10463516
[TBL] [Abstract][Full Text] [Related]
8. ACTG 175 and Delta.
Torres G
GMHC Treat Issues; 1995 Oct; 9(10):2-3. PubMed ID: 11362915
[TBL] [Abstract][Full Text] [Related]
9. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
Ibáñez A; Peraire J; Arnó A; Gutiérrez C; Cervantes M; Colomer J; Villalonga C; Camafort M; Ruiz L; Balaguer M; Vidal F; Richart C; Clotet B
Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274
[TBL] [Abstract][Full Text] [Related]
10. Studies confirm value of early and combination treatments.
Vazquez E
Posit Aware; 1995; VI(6):8. PubMed ID: 11363148
[TBL] [Abstract][Full Text] [Related]
11. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus retinitis under combination therapy with zidovudine and dideoxycytidine in advanced human immunodeficiency virus infection.
Kaulen P; Pham DT; Baranowski E; Wollensak J
Ger J Ophthalmol; 1993 Nov; 2(6):412-5. PubMed ID: 8312826
[TBL] [Abstract][Full Text] [Related]
13. 3TC approval may revive AZT's appeal.
Vazquez E
Posit Aware; 1996; 7(1):8-9. PubMed ID: 11363136
[TBL] [Abstract][Full Text] [Related]
14. AZT, ddI, and ddC combinations at FDA advisory hearing. Food and Drug Administration.
James JS
AIDS Treat News; 1996 Apr; (no 244):6. PubMed ID: 11363307
[TBL] [Abstract][Full Text] [Related]
15. [Sequential dideoxycytidine and zidovudine in advanced HIV-1 infection. Phase II study].
Ruiz-Argüelles GJ; Lagunes-Yannelli B; Mercado-Díaz L
Rev Invest Clin; 1993; 45(2):145-7. PubMed ID: 8393211
[TBL] [Abstract][Full Text] [Related]
16. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
Lancet; 1996 Aug; 348(9023):283-91. PubMed ID: 8709686
[TBL] [Abstract][Full Text] [Related]
17. Researchers are rethinking role of AZT in drug therapy.
AIDS Policy Law; 1995 Oct; 10(18):11. PubMed ID: 11362821
[TBL] [Abstract][Full Text] [Related]
18. Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
Izopet J; Sailler L; Sandres K; Pasquier C; Bonnet E; Aquilina C; Puel J; Massip P; Marchou B
J Med Virol; 1999 Feb; 57(2):163-8. PubMed ID: 9892402
[TBL] [Abstract][Full Text] [Related]
19. AZT studies reinforce benefits of combination.
AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167
[TBL] [Abstract][Full Text] [Related]
20. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
Shirasaka T; Yarchoan R; O'Brien MC; Husson RN; Anderson BD; Kojima E; Shimada T; Broder S; Mitsuya H
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):562-6. PubMed ID: 8380641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
